Skip to content
vaccines hero image
vaccines hero image

Vaccines

Vaccines contain antigenic substances capable of inducing immunity against an infective agent or toxin.

They are frequently administered prophylactically but are increasingly being researched and developed in a therapeutic context (eg cancer vaccines which are designed to equip a patient’s immune system to treat an existing cancer).

While the global market for vaccines is less than 3% of the total pharmaceuticals market, World Health Organization research suggests that over the next few years, the vaccine market will enjoy a growth rate of 10% to 15% per year versus the 5% to 7% seen in the overall market.

To take a share of this expanding market, companies must navigate a number of challenges. The assessment, licensing and control of vaccines (which are biological medicinal products) occurs in an environment of rapid innovation and complex quality concerns. Our deep experience of vaccines, combined with the fact that our team includes lawyers with degrees in relevant scientific areas (molecular biology, biochemistry, genetics etc), enables us to quickly grasp evolving issues and technical concepts and provide nuanced and tailored advice.

We are trusted by many of the world’s leading vaccine companies to help them navigate all stages of the vaccine lifecycle. Our clients include Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer and Novartis.

News & insights

Close up of data screen with figures

News: 12 FEBRUARY 2021

Allen & Overy advises Biogroup on two high-yield bond issues and a new senior facilities agreement

PARIS – Biogroup, the leading private medical laboratory services group in France and Belgium, has successfully completed through its two main subsidiaries the issuance of EUR800million in aggregate…

Read more
City skyline

News: 01 FEBRUARY 2021

Allen & Overy continues to make gains with FTSE clients

In the Adviser Rankings 15th anniversary guide A&O is ranked 3rd for FTSE 100 with 23 clients, up from 17 in 2010, and A&O is one of only two magic circle firms to have grown their total stock market…

Read more
Euro note with china flag overlay

Publications: 11 JANUARY 2021

Will the EU-China Comprehensive Agreement facilitate investment by EU companies in China?

The European Union (EU) and the People’s Republic of China concluded the negotiations on their investment treaty, the EU/China Comprehensive Agreement on Investment (CAI), on 30 December 2020. 

Read more
Vials of medication during production

Publications: 15 DECEMBER 2020

Healthcare accent is on smaller deals

Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years. 

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2021

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.